Key result
Cardiac resynchronization therapy improves ejection fraction and clinical symptoms in pediatric patients with pacemaker-induced cardiomyopathy, though its efficacy in other congenital heart diseases remains variable.
Why the study?
Does cardiac resynchronization therapy improve clinical and echocardiographic outcomes in pediatric and congenital heart disease patients?
Does cardiac resynchronization therapy improve clinical and echocardiographic outcomes in pediatric and congenital heart disease patients?
CRT is highly effective for pediatric patients with pacemaker-induced cardiomyopathy, but its application in other pediatric heart failure etiologies requires further study due to anatomical and physiological heterogeneity.
Supports CRT consideration in pediatric pacemaker-induced cardiomyopathy; leaves open its role in other congenital heart diseases pending prospective data.
Cardiac resynchronization therapy (CRT) has proven to be a powerful and effective tool in the treatment of adults with severe dilated or ischemic cardiomyopathy. A substantial portion of the adult heart failure population has severely depressed systolic function, heart failure symptoms, QRS prolongation, and left bundle branch block. Indications for CRT in adults are commonly focused on these characteristics. However, pediatric patients represent a heterogeneous group with many etiologies of heart failure and anatomic variants, with most of them not fitting the typical adult CRT criteria. The heterogeneity of the pediatric population has hindered the identification of ideal candidates for CRT, but initial experience with CRT in various groups of pediatric patients has been encouraging. This article reviews indications for and outcomes of CRT in pediatric and congenital heart disease patients.
No takes yet. Share an insight, caveat, or question.
Hill et al. (2018) conducted a review in Pediatric heart failure and congenital heart disease. Cardiac Resynchronization Therapy (CRT) was evaluated. Cardiac resynchronization therapy improves ejection fraction and clinical symptoms in pediatric patients with pacemaker-induced cardiomyopathy, though its efficacy in other congenital heart diseases remains variable.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: